Trevena, Inc. TRVN
Regular-session close
- YTD
- -95.83%
- 1 year
- -95.83%
- Market cap
- 431
- EPS (ttm)
- -2.20
- Shares out
- 852.93K
- Forward P/E
- -0.09
- YTD return
- -95.83%
- 1-year return
- -95.83%
- 50-day average
- 3.32
- 200-day average
- 8.10
- Volume
- 210
- Avg volume
- 199
- Open
- 0.012
- Previous close
- 0.0005
- Day's range
- 0.012 – 0.012
- 52-week range
- 0.0003 – 0.066
- Analysts
- Buy
- Price target
- 100.00 (+19999900.0%)
Key statistics
- Short % of float
- 7.03%
Fundamental scorecard
5 of 25 checks passed on TRVN’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 1 of 5
- Financial health 2 of 5
- Dividend 0 of 5
Statements to Jun 30, 2024.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | 0.00 | -5.79 | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -9.25 | -5.75 | +3.50 | +37.84% |
| May 15, 2024 | Mar 1, 2024 | -9.25 | -9.00 | +0.25 | +2.70% |
| Apr 1, 2024 | Dec 1, 2023 | -13.00 | -26.50 | -13.50 | -103.85% |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -14.25 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | -11.25 | -17.25 | -6.00 | -53.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 16, 2023 | JMP Securities | reit | Market Outperform | Market Outperform |
| Mar 30, 2023 | HC Wainwright & Co. | reit | — | Buy |
| Mar 30, 2023 | JMP Securities | reit | — | Market Outperform |
About Trevena, Inc.
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- trevena.com
News
Trevena (NASDAQ:TRVN) Share Price Crosses Above 50-Day Moving Average – Here’s What Happened
Critical Contrast: Ampio Pharmaceuticals (NYSE:AMPE) vs. Trevena (NASDAQ:TRVN)
Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc.; Mountain Crest Acquisition Corp. V; and bleuacacia ltd from The Nasdaq Stock Market
Trevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Trevena Reports Third Quarter 2024 Results and Provides Business Update
Trevena Announces Receipt of Nasdaq Delisting Notification
Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing
What's Going On With Neurological Disease Focused Trevena On Thursday?
Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models
Trevena, Inc. to Post Q2 2024 Earnings of ($0.37) Per Share, HC Wainwright Forecasts (NASDAQ:TRVN)
Your note
Sign in to keep a note on TRVN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOURDOW CARRIE L | Chief Executive Officer | Stock Award(Grant) | Dec 13, 2023 | 642,923 |
| DEMITRACK MARK A | Officer | Stock Award(Grant) | Dec 13, 2023 | 306,224 |
| DRAKE PATRICIA M | Officer | Stock Award(Grant) | Dec 13, 2023 | 107,078 |
| SHIN BARRY | Chief Financial Officer | Stock Award(Grant) | Dec 13, 2023 | 308,821 |
| YODER ROBERT T. | Officer | Stock Award(Grant) | Dec 13, 2023 | 158,877 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 1.33% | 182,152 | 160.47K | Jun 29, 2023 |
| Blackrock Inc. | 0.82% | 112,173 | 98.82K | Jun 29, 2023 |
| Vanguard Group Inc | 0.53% | 72,812 | 64.15K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.48% | 65,167 | 57.41K | Jun 29, 2023 |
| Simplex Trading, LLC | 0.27% | 37,590 | 33.12K | Jun 29, 2023 |
| Captrust Financial Advisors | 0.24% | 33,076 | 29.14K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.51% | 70,176 | 61.83K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.24% | 33,095 | 37.73K | May 30, 2023 |
| Fidelity OTC Portfolio | 0.13% | 17,806 | 15.49K | Aug 30, 2023 |
| Fidelity Total Market Index Fund | 0.07% | 8,946 | 10.20K | May 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 7,457 | 8.50K | May 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.05% | 7,358 | 8.39K | May 30, 2023 |
